Adjuvant therapy for resected non-small-cell lung cancer: Past, present, and future

Rosalyn A. Juergens, Julie R. Brahmer

Research output: Contribution to journalReview articlepeer-review

Abstract

Non-small-cell lung cancer has the highest mortality of all malignancies worldwide. Unfortunately, only the minority of patients diagnosed will have potentially curable disease. Over the past 30 years, dozens of trials have been conducted assessing adjuvant treatments to augment the survival advantage offered by surgery. It has only been in the past 5 years that promising results have begun to be seen. Cisplatin-based therapy has now been shown to provide an additional survival benefit in several trials and in a recent meta-analysis. The goal of this paper is to review the data on adjuvant therapies that have emerged over the past 30 years, focusing specifically on the trials that have been published in the past 5 years.

Original languageEnglish (US)
Pages (from-to)248-254
Number of pages7
JournalCurrent oncology reports
Volume7
Issue number4
DOIs
StatePublished - Jul 2005

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Adjuvant therapy for resected non-small-cell lung cancer: Past, present, and future'. Together they form a unique fingerprint.

Cite this